ZNF217 and breast cancer: Therefore Aurora-A is certainly part of the mechanism by which ZNF217 controls resistance to paclitaxel, and the use of a potent Aurora-A inhibitor could be sufficient to reverse ZNF217-mediated paclitaxel resistance in MDA-MB-231 breast cancer cells.